Mayo Clinic patented a method to create viruses like measles and adenoviruses with reduced susceptibility to antibody neutralization. The patent involves recombinant morbilliviruses with modified H and F genes. The claim specifies a recombinant virus with specific amino acid substitutions in the H polypeptide. GlobalData’s report on Mayo Clinic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Mayo Clinic, was a key innovation area identified from patents. Mayo Clinic's grant share as of May 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Modified measles virus with reduced susceptibility to antibody neutralization
A recently granted patent (Publication Number: US12011479B2) discloses a recombinant virus comprising a nucleic acid encoding a measles virus H polypeptide with specific amino acid substitutions and a nucleic acid encoding a morbillivirus F polypeptide other than a measles virus F polypeptide. The patented virus is designed to exhibit CD46-dependent cell entry and reduced Nectin-4-dependent cell entry, potentially useful for reducing viable tumor cells in mammals. The patent also covers methods for reducing tumor cells and stimulating an immune response against measles virus in mammals by administering the recombinant virus, particularly in humans and infants with transplacentally acquired anti-measles antibodies.
Furthermore, the patent includes a nucleic acid construct with specific amino acid substitutions in the measles virus H polypeptide and a morbillivirus F polypeptide, suitable for use as a viral vector derived from various viruses like adenovirus, retrovirus, and vaccinia virus. The construct aims to enhance immune responses against measles virus and can be utilized without encoding the wild-type measles virus H polypeptide or the measles virus F polypeptide. This patent provides a novel approach to developing recombinant viruses for therapeutic purposes, particularly in cancer treatment and immune response stimulation against measles virus, with potential applications in human and infant populations.
To know more about GlobalData’s detailed insights on Mayo Clinic, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
